#novonordisk #weightloss #stockmarket #yahoofinance

Shares of Novo Nordisk (NVO) have hit a record high on phase 1 trial data from Amycretin, its latest weight loss product. The new drug shows over 13% weight loss in users after 12 weeks of use, more than double Wegovy's efficacy over the same time period. Yahoo Finance Health Reporter Anjalee Khemlani joins the Live show to break down the limitations of this data and what to expect from additional testing phases. For more expert insight and the latest market action, click here to watch the full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino

About Yahoo Finance:

Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.

- Get the latest news and data at finance.yahoo.com

- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)

- Follow Yahoo Finance on social:

X:   / yahoofinance  
Instagram: https://www.instagram.com/yahoofinanc...
TikTok: https://www.tiktok.com/@yahoofinance?...
Facebook:   / yahoofinance  
LinkedIn:   / yahoo-finance